ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "Biologics and rheumatoid arthritis (RA)"

  • Abstract Number: 2832 • ACR/ARHP Annual Meeting 2017

    Finding the Optimal Treatment Strategy for Disease Activity-Guided Dose Reduction of Adalimumab and Etanercept in Rheumatoid Arthritis: A Modelling Study

    D.P.G. Bos1, L.M. Verhoef1, C.H.M. van den Ende1,2, F.H.J. van den Hoogen1,2, Bruno Fautrel3,4, M.E.J.L. Hulscher5, W. Kievit6 and A.A. Den Broeder1,2, 1Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2Rheumatology, Radboud university medical centre, Nijmegen, Netherlands, 3UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, 4Paris VI Pierre et Marie Curie University, Paris, France, 5Radboud Institute for Health Sciences, IQ healthcare, Radboud university medical centre, Nijmegen, Netherlands, 6Department for Health Evidence, Radboud university medical centre, Nijmegen, Netherlands

    Background/Purpose: Although bDMARDs are often able to control the RA, they are expensive and associated with adverse effects. Therefore, it is important to use the…
  • Abstract Number: 599 • ACR/ARHP Annual Meeting 2016

    Real World United States-Based Clinical Experience with Prior Biologic Use Among First Time Golimumab Intravenous and Infliximab Treated Rheumatoid Arthritis Patients

    Sergio Schwartzman1, Dennis Parenti2, Shawn Black2, Kehzen Tang3, Yanli Wang3 and Shelly Kafka2, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Janssen Scientific Affairs, LLC, Horsham, PA, 3Janssen Research & Development, LLC, Spring House, PA

    Background/Purpose:  AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is a Phase 4 comparator study designed to provide a real-world…
  • Abstract Number: 1611 • ACR/ARHP Annual Meeting 2016

    In Vitro Cellular Profiling of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Reveals a Distinct Phenotypic Signature Compared to Tocilizumab, an Anti–IL-6 Receptor Monoclonal Antibody

    Konstantia-Maria Chavele1, Debbie Gardner2, Matthew J Loza2, Bidisha Dasgupta2, Martin Sims1, David Shealy2, Juliet Reid1 and Ravi Rao1, 1GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom, 2Janssen Research & Development, LLC, Spring House, PA

    Background/Purpose:  IL-6 plays a central pathogenic role in rheumatoid arthritis (RA). IL-6 signals through a complex of transmembrane IL-6R or soluble IL-6R (sIL-6R) with gp130…
  • Abstract Number: 444 • ACR/ARHP Annual Meeting 2015

    TNF Inhibitor Use Across Countries in Two Time Periods Using the Meteor Database

    Karen Salomon-Escoto1, Nisha Kini1, Sharina D. Person1, J.A.P. da Silva2, Gianfranco Ferraccioli3, T. W. J. Huizinga4, Robert B.M. Landewé5, RJ Moots6, D. van der Heijde7, Douglas J. Veale8, Ellen M. Gravallese1 and Jonathan Kay1, 1University of Massachussets Medical School, Worcester, MA, 2Centro Hospitalar e Universitário de Coimbra - Hospitais da Universidade de Coimbra, EPE, Coimbra, Portugal, 3Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy, 4Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 6Department of Musculoskeletal Biology, University of Liverpool, Liverpool, United Kingdom, 7Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 8Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland

    Background/Purpose: Biologic agents are effective treatment for rheumatoid arthritis (RA), but factors exist that may influence the prescription of these drugs in different countries. We…
  • Abstract Number: 1649 • ACR/ARHP Annual Meeting 2015

    Long-Term Safety and Efficacy of Olokizumab in Patients with Moderate-to-Severe Rheumatoid Arthritis Who Have Previously Failed Anti-TNF Treatment

    Mark C. Genovese1, Roy Fleischmann2, Yoshiya Tanaka3, Daniel E. Furst4, Hisashi Yamanaka5, Rajesh Joshi6, Wei Zhu7, Jing Shao8, Hideki Mashimo8 and Tsutomu Takeuchi9, 1Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, 2Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX, 3The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 4Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 5Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 6Quintiles Inc., Mumbai, India, 7UCB Pharma, Raleigh, NC, 8UCB Pharma, Tokyo, Japan, 9Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Olokizumab (OKZ) is a humanized anti-interleukin-6 monoclonal antibody in development for moderate-to-severe rheumatoid arthritis (RA) treatment. OKZ efficacy and safety were assessed in the…
  • Abstract Number: 2775 • ACR/ARHP Annual Meeting 2015

    What Factors Are Associated with Starting an Intravenous Vs. Sub-Cutaneous Biologic in Patients with RA?

    Kaleb Michaud1,2, Sofia Pedro2 and Steven Peterson3, 1Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 2National Data Bank for Rheumatic Diseases, Wichita, KS, 3Janssen Global Services, LLC, Malvern, PA

    Background/Purpose: To characterize which factors are associated with RA patients' preferences for biologic administration: sub-cutaneous or intravenous.Methods: Using a large US observational cohort, the National…
  • Abstract Number: 2529 • ACR/ARHP Annual Meeting 2014

    Efficacy of Infliximab, Adalimumab, and Tocilizumab Can be Improved Under the Baseline ADAMTS5 Selection

    Kensei Tsuzaka1,2, Yoko Akiyama2 and Masayoshi Nagata1, 1Division of Rheumatology, Iruma Heart Hospital, Iruma, Saitama, Japan, 2Kaytee Bio, Co&Ltd, Funabashi, Chiba, Japan

    a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) mRNA level. In this study presented here, we investigated whether the efficacy of these biologics could…
  • Abstract Number: 996 • ACR/ARHP Annual Meeting 2014

    Memory B Cell Subtype Modulation in Patients with Rheumatoid Arthritis

    Zafar Mahmood1, Marc Schmalzing2, Thomas Dörner3 and Hans-Peter Tony2, 1Rheumatology and Clinical Immunology, University of Würzburg, Würzburg, Germany, 2Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, 3Charité Universitätmedizin Berlin and DRFZ, Berlin, Germany

    Background/Purpose . Memory B cells have been shown to play important roles in the pathogenesis of rheumatoid arthritis (RA). With the advent of B cell…
  • Abstract Number: 499 • ACR/ARHP Annual Meeting 2014

    Biologic Discontinuation in Rheumatoid Arthritis: Experience from a Canadian Clinic

    Denis Choquette1, Louis Coupal1, Marie-Claude Laliberté2 and Olivier Desjardins2, 1Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 2AbbVie, St. Laurent, QC, Canada

    Background/Purpose: Adherence and persistence to treatment are a cornerstone of treatment success in chronic diseases such as rheumatoid arthritis (RA). The purpose of this study…
  • Abstract Number: 466 • ACR/ARHP Annual Meeting 2013

    Biologic Monotherapy in French Rheumatoid Arthritis (RA) Patients From a Real-Life Clinical Practice Compared To Patients Treated with a Combination Therapy (Biologic + DMARD)

    Philippe Dieude1, Chantal Deslandre2, Emilie Desfleurs3, Jeanne Antheaume3 and Jean-Charles Balblanc4, 1Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, 2Rheumatology, Cochin Hospital, Paris, France, 3Rheumatology, Roche SAS, Boulogne-Billancourt, France, 4Rheumatology, Centre Hospitalier Général de Belfort, Belfort, France

    Background/Purpose: Combination therapy (Biologic+non-biologic (nb)DMARDs) is the recommended therapeutic strategy in biologic-based RA treatment. However, biologics in montherapy represent around 30% of the biologic-treated patients…
  • Abstract Number: 435 • ACR/ARHP Annual Meeting 2013

    Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized, Placebo-Controlled Trial Of Golimumab In Methotrexate-naïve Patients With Rheumatoid Arthritis

    Paul Emery1, Roy Fleischmann2, Ingrid Strusberg3, Patrick Durez4, Peter Nash5, Eric Amante6, Melvin A. Churchill7, Won Park8, Bernardo Pons-Estel9, Chenglong Han10, Timothy A. Gathany10, Yiying Zhou11, Stephen Xu12 and Elizabeth C. Hsia12, 1Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and NIHR LMBRU, Leeds, United Kingdom, 2University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 3Instituto Reumatológico Strusberg, Cordoba, Argentina, 4Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, 5University of Queensland, Brisbane, Australia, 6University of Phillipines General Hospital, Manila, Philippines, 7Arthritis Center of Nebraska, Lincoln, NE, 8Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, 9Sanatorio Parque, Rosario, Argentina, 10Janssen Global Services, LLC., Malvern, PA, 11Biostatistics, Janssen Research & Development, LLC., Spring House, PA, 12Janssen Research & Development, LLC., Spring House, PA

    Background/Purpose: Final 5yr safety and efficacy results of subcutaneous golimumab (GLM)+/-MTX evaluated in a phase 3 trial (GO-BEFORE) of MTX-naïve pts with rheumatoid arthritis (RA)…

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology